Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 31 to 40 of 365 total matches.
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
acne, but it is teratogenic and has many adverse effects.
The Medical Letter ® Vol. 66 (1695) February ...
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20 doi:10.58347/tml.2024.1695a | Show Introduction Hide Introduction
Drugs for Rosacea
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
-skinned
patients, and purpura.1,16
The Medical Letter ® Vol. 66 (1695) February 5, 2024 Flagyl ...
Rosacea is a common, chronic inflammatory facial
eruption of unknown cause. It is more prevalent
in women than in men, and disease onset typically
occurs after age 30. Rosacea is characterized
by erythema, telangiectasia, and flushing, and
sometimes by recurrent, progressive crops of
acneiform papules and pustules, usually on the
central part of the face. Some patients develop
granulomas and tissue hypertrophy, which may lead
to rhinophyma (a bulbous nose), particularly in men.
Blepharitis and conjunctivitis are common. Keratitis
and corneal scarring occur rarely.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):21-2 doi:10.58347/tml.2024.1695b | Show Introduction Hide Introduction
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
no dose no dose
1. For iron deficiency in adults with heart failure.
The Medical Letter ® Vol. 66 (1695 ...
Ferric carboxymaltose (Injectafer – American
Regent) is now FDA-approved for IV treatment of iron
deficiency in adults with New York Heart Association
(NYHA) class II/III heart failure to improve exercise
capacity. Iron deficiency is present in approximately
30% of patients with heart failure; it has been
associated with reduced quality of life and increased
hospitalization and mortality. Injectafer is the first
IV iron preparation to be approved for this indication.
It was previously approved for treatment of iron
deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4 doi:10.58347/tml.2024.1695d | Show Introduction Hide Introduction
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
. The primary endpoint, an
The Medical Letter ® Vol. 66 (1694) January 22, 2024
10
absence of severe vaso ...
Two cell-based gene therapies – exagamglogene
autotemcel (Casgevy – Vertex) and lovotibeglogene
autotemcel (Lyfgenia – Bluebird Bio) – have been
approved by the FDA for treatment of sickle cell
disease in patients ≥12 years old with recurrent vaso-occlusive
crises. They are the first gene therapies to
be approved in the US for use in sickle cell disease;
Casgevy is the first treatment to be approved in the
US that uses CRISPR/Cas9 gene-editing technology.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):9-10 doi:10.58347/tml.2024.1694a | Show Introduction Hide Introduction
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
completely than blocking IL-17A alone.
The Medical Letter ® Vol. 66 (1694) January 22, 2024
12
Table 1 ...
The FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx
– UCB) for treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
treatment or phototherapy. Bimekizumab is the first
IL-17A/17F antagonist to be approved in the US. It
was approved in the European Union for the same
indication in 2021.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):11-3 doi:10.58347/tml.2024.1694b | Show Introduction Hide Introduction
Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
and
symptoms of dry eye disease (see Table 1).8,9
The Medical Letter ® Vol. 66 (1694) January 22, 2024
14 ...
The FDA has approved perfluorohexyloctane
ophthalmic solution (Miebo – Bausch+Lomb) for
treatment of dry eye disease. Available only by
prescription, Miebo is the first ophthalmic product to be approved in the US that specifically targets tear
evaporation caused by meibomian gland dysfunction.
An ophthalmic solution with a similar name, Meibo
Tears (Vista), which contains 0.6% propylene glycol, is
available over the counter for dry eye relief.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):13-4 doi:10.58347/tml.2024.1694c | Show Introduction Hide Introduction
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
The Medical Letter ® Vol. 66 (1694) January 22, 2024
16
In GATHER1, avacincaptad pegol remained effective ...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 doi:10.58347/tml.2024.1694d | Show Introduction Hide Introduction
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
and
produced durable responses in those who had treatmentrefractory
disease.
e17
The Medical Letter ® Vol ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
on thromboembolic risk determined by a
clinical risk scoring system such as CHA2DS2-VASc
The Medical Letter ® Vol ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Zuranolone (Zurzuvae) – An Oral Drug for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
according to the manufacturer.
The Medical Letter ® Vol. 65 (1692) December 25, 2023
1. Brexanolone ...
The FDA has approved the oral GABAA receptor
modulator zuranolone (Zurzuvae – Sage Therapeutics/Biogen) for treatment of postpartum depression
(PPD). Zuranolone is the second drug to be approved
for this indication; brexanolone (Zulresso), another
GABAA receptor modulator, was approved for IV
treatment of PPD in 2019.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):201-3 doi:10.58347/tml.2023.1692a | Show Introduction Hide Introduction